bafilomycin-a1 and Leukemia--Myeloid

Bafilomycin A1, a selective inhibitor of vacuolar H+-ATPase, time- and dose-dependently induced the differentiation of M1 cells, a murine myeloid leukemic cell line, into macrophage-like cells as revealed by the phagocytosis of polystyrene latex particles. This differentiation was inhibited not only by actinomycin D and cycloheximide but also by ST-638 (an inhibitor of tyrosine kinase). However, it was affected neither by K-252a (an inhibitor of C-kinase) nor by H-89 (an inhibitor of A-kinase), in contrast to the M1 cell differentiation induced by leukemia inhibitory factor (LIF). Okadaic acid inhibited both the bafilomycin A1-induced and LIF-induced differentiation of M1 cells.

Topics: Animals; Anti-Bacterial Agents; Carbazoles; Cinnamates; Ethers, Cyclic; Growth Inhibitors; Indole Alkaloids; Interleukin-6; Isoquinolines; Leukemia Inhibitory Factor; Leukemia, Myeloid; Lymphokines; Macrolides; Macrophages; Mice; Okadaic Acid; Phagocytosis; Phosphoprotein Phosphatases; Phosphorylation; Protein Biosynthesis; Protein Kinase C; Protein Kinase Inhibitors; Proton-Translocating ATPases; RNA; Sulfides; Sulfonamides; Tumor Cells, Cultured; Vacuoles

HL60 cells isolated for resistance to vincristine (HL60/Vinc cells) or doxorubicin (HL60/Adr cells) contain enhanced levels of an energy-dependent drug efflux pump. HL60/Vinc cells contain the drug transporter P-glycoprotein, whereas the HL60/Adr isolate does not. In the present study, we examined the possible involvement of vacuolar H(+)-adenosine triphosphatase (H(+)-ATPase) activity in drug resistance in HL60 cells. We utilized bafilomycin A1, an agent which selectively inhibits vacuolar H(+)-ATPase activity at low concentrations. The results showed that bafilomycin A1 induced a major increase in drug accumulation and inhibited drug efflux in both HL60/Adr cells and HL60/Vinc cells. Similar results were obtained with 7-chloro-4-nitrobenz-2-oxa 1,3 diazole, an agent which is also capable of inhibiting vacuolar H(+)-ATPase. Azide, an inhibitor of F1F0 mitochondrial ATPase, and vanadate and ouabain, which are inhibitors of E1E2-type ATPase, did not affect drug levels in resistant cells. We also observed that bafilomycin A1 did not compete with [3H]azidopine binding to P-glycoprotein. Thus, bafilomycin A1 does not appear to function as a substrate for P-glycoprotein. These results suggest an involvement of vacuolar H(+)-ATPase activity in the pathway of drug efflux from HL60/Adr cells and HL60/Vinc cells. The mechanism of this action remains to be determined.

Topics: Anti-Bacterial Agents; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Leukemia, Experimental; Leukemia, Myeloid; Macrolides; Proton-Translocating ATPases; Tritium; Tumor Cells, Cultured; Vacuoles; Vincristine